JAN’s Quiet Period To Expire on April 29th (NYSE:JAN)

JAN’s (NYSE:JAN) quiet period will expire on Wednesday, April 29th. JAN had issued 42,000,000 shares in its IPO on March 20th. The total size of the offering was $840,000,000 based on an initial share price of $20.00. During JAN’s quiet period, insiders and underwriters involved in the IPO are prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Analyst Upgrades and Downgrades

JAN has been the subject of a number of analyst reports. KeyCorp initiated coverage on JAN in a research note on Tuesday, April 14th. They set an “overweight” rating and a $28.00 price objective for the company. Bank of America started coverage on shares of JAN in a research report on Tuesday, April 14th. They issued a “buy” rating and a $29.00 price objective for the company. Royal Bank Of Canada started coverage on shares of JAN in a research report on Tuesday, April 14th. They issued an “outperform” rating and a $27.00 price objective for the company. Wells Fargo & Company started coverage on shares of JAN in a research report on Tuesday, April 14th. They issued an “overweight” rating and a $27.00 price objective for the company. Finally, The Goldman Sachs Group started coverage on shares of JAN in a research report on Tuesday, April 14th. They issued a “neutral” rating and a $27.00 price objective for the company. Ten analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $27.27.

JAN Price Performance

JAN opened at $24.74 on Friday. JAN has a 12 month low of $22.76 and a 12 month high of $26.70. The firm has a market capitalization of $6.36 billion, a P/E ratio of -62.29 and a beta of 2.16.

Insiders Place Their Bets

In other news, CEO Scott M. Brinker bought 100,000 shares of the stock in a transaction on Monday, March 23rd. The stock was purchased at an average price of $20.00 per share, for a total transaction of $2,000,000.00. Following the acquisition, the chief executive officer owned 100,000 shares in the company, valued at approximately $2,000,000. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Katherine M. Sandstrom bought 13,500 shares of the stock in a transaction on Monday, March 23rd. The shares were purchased at an average price of $20.00 per share, with a total value of $270,000.00. Following the acquisition, the director owned 21,000 shares in the company, valued at approximately $420,000. This represents a 180.00% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased 187,000 shares of company stock worth $3,740,000 over the last 90 days. 3.00% of the stock is currently owned by corporate insiders.

More JAN News

Here are the key news stories impacting JAN this week:

• Positive Sentiment: Analyst support: H.C. Wainwright reiterated a bullish stance and buy rating, highlighting progress in the company’s PSMA franchise and validation of its TRACTr platform — a vote of confidence from the sell‑side that can attract momentum buyers and institutional interest. Advancing PSMA Franchise and Validating TRACTr Platform Underpin Buy Rating on Janux Therapeutics
• Positive Sentiment: Clinical catalyst: TipRanks reports the company’s JANX011 first‑in‑human study is ongoing and an early safety readout is expected — a successful safety signal would materially expand the stock’s upside by validating the program’s potential in autoimmune indications (conversely, trial risk remains). This type of near‑term data event often drives biotech moves. Janux’s JANX011 First‑in‑Human Study: Early Safety Readout Could Shape Autoimmune Upside
• Neutral Sentiment: Quiet period ending: Coverage notes that JAN’s quiet period ends April 29 — once the quiet period lifts the company can comment publicly and disclose more detail on programs or upcoming catalysts, which can increase information flow and trading activity. That scheduling alone can support a stock re‑rating but is not a direct fundamental change. JAN’s Quiet Period Will End on April 29th (NYSE:JAN)

JAN Company Profile

Upon completion of this offering, we will be the only U.S. publicly traded REIT focused exclusively on the senior housing sector and the only U.S. publicly traded REIT whose entire portfolio is owned and operated under RIDEA structures. We have an initial portfolio consisting of 34 senior housing communities, comprised of 10,422 units as of December 31, 2025. Our communities are located primarily in major retirement markets across 10 states, with units in Florida and Texas representing 69% of the total units as of December 31, 2025.